ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 075,68
0,99%
Dow Jones
38 884,26
0,08%
DAX
18 430,05
1,42%
Brent Oil
82,675
-0,23%
Bitcoin
62 666,64
0,53%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cognition Therapeutics Inc (CGTX)

  7. Cognition Therapeutics Inc (CGTX) Actualités

CGTX Cognition Therapeutics Inc

1,92
-0,07 (-3,52%)
08 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Cognition Therapeutics Inc CGTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,07 -3,52% 1,92 00:44:37
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,98 1,9001 2,00 1,92 1,99
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
07/5/202413:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202413:39EDGAR2Form 8-K - Current report
11/3/202421:11EDGAR2Form 8-K - Current report
11/3/202421:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/2/202422:44EDGAR2Form 8-K - Current report
20/2/202422:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/2/202401:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202421:07EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
08/1/202422:11EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
04/1/202422:21EDGAR2Form 8-K - Current report
04/1/202413:30GLOBECognition Therapeutics CEO Issues Letter to Shareholders
29/12/202322:02EDGAR2Form S-3 - Registration statement under Securities Act of..
16/11/202313:30GLOBECognition Therapeutics Releases New Episode of..
15/11/202313:30GLOBECognition Therapeutics Presents Preclinical Data Identifying..
13/11/202323:25EDGAR2Form SC 13D/A - General statement of acquisition of..
13/11/202315:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202315:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202313:30GLOBECognition Therapeutics Completes Enrollment in Phase 2 SHINE..
02/11/202312:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202312:41EDGAR2Form 8-K - Current report
02/11/202312:30GLOBECognition Therapeutics Reports Third Quarter 2023 Financial..
27/10/202313:30GLOBECognition Therapeutics and Collaborators at Yale and ACTC..
24/10/202322:30GLOBECognition Therapeutics Presents Complete EEG Findings from..
16/10/202313:30GLOBECognition Therapeutics Presents New Data at CTAD Conference..
12/9/202313:00EDGAR2Form 8-K - Current report
07/9/202313:45GLOBECognition Therapeutics Announces New Conversations Episode..
30/8/202314:00GLOBECognition Therapeutics Announces Participation in Upcoming..
24/8/202313:00EDGAR2Form 8-K - Current report
08/8/202313:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202313:05EDGAR2Form 8-K - Current report
08/8/202313:00GLOBECognition Therapeutics Reports Second Quarter 2023 Financial..
02/8/202313:30GLOBECognition Therapeutics to Report Second Quarter 2023 Results..
11/7/202313:30GLOBECognition Therapeutics Announces Dosing of First Patient in..
05/7/202313:30GLOBECognition Therapeutics and the Alzheimer's Clinical Trials..
28/6/202313:00GLOBECognition Therapeutics Announces Positive Topline Results..
28/6/202301:17GLOBECognition Therapeutics to Host Call and Webcast to Discuss..
20/6/202313:30GLOBECognition Therapeutics Invited to Participate on Panel..
02/6/202313:30GLOBECognition Therapeutics Continues Investor Engagement in June..
23/5/202313:30GLOBECognition Therapeutics Latest Episode of “Conversations”..
18/5/202313:30GLOBECognition Therapeutics Publishes Clinical Evidence that..

Dernières Valeurs Consultées

NASDAQ
CGTX
Cognition Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés